SMS Pharmaceuticals reports robust Q2FY24 operational performance
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
General Medicine grows 5% and Vaccines 10% led by Shingrix
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Total transaction value of the divestment is Rs. 3,660 million
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
Subscribe To Our Newsletter & Stay Updated